Oral GLP-1 Candidate Aleniglipron Shows Robust Weight Loss and Favorable Tolerability in Phase 2 Program
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral small-molecule glucagon-like peptide‑1 (GLP‑1) receptor…
Continue Reading
Oral GLP-1 Candidate Aleniglipron Shows Robust Weight Loss and Favorable Tolerability in Phase 2 Program
